- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
Culver City Today
By the People, for the People
ImmunityBio Secures $100M in Financing to Bolster Balance Sheet
Funding to support global expansion and advancement of immunotherapy pipeline following recent regulatory approvals.
Mar. 31, 2026 at 1:21pm
Got story updates? Submit your updates here. ›
ImmunityBio's latest financing transactions strengthen the company's balance sheet to support the global expansion and advancement of its innovative immunotherapy treatments.Culver City TodayImmunityBio, Inc., a commercial-stage immunotherapy company, has secured $100 million in financing transactions, including $75 million in non-dilutive funding under its existing Revenue Interest Purchase Agreement (RIPA) with Oberland Capital. Simultaneously, ImmunityBio's Executive Chairman's entity, Nant Capital, LLC, converted $25 million of outstanding debt into equity, further strengthening the company's balance sheet.
Why it matters
The additional financing and debt reduction will enable ImmunityBio to continue scaling its commercial efforts and expanding globally following recent regulatory approvals for its lead immunotherapy product, ANKTIVA®. The funding will also support the advancement of ImmunityBio's broader immunotherapy pipeline.
The details
Under the amended RIPA, ImmunityBio will receive $75 million in non-dilutive financing, bringing the total committed capital to $375 million. The agreement maintains existing terms, with a modest increase in the royalty payback rate while maintaining the royalty cap. Simultaneously, Nant Capital, LLC, an entity affiliated with ImmunityBio's Executive Chairman, converted $25 million of the outstanding promissory note into 4.6 million shares of the company's common stock, reducing the company's debt.
- ImmunityBio's ANKTIVA® was approved by the U.S. FDA in April 2024.
- ANKTIVA® was authorized by the UK's MHRA in July 2025.
- ANKTIVA® received accelerated approvals from the Saudi FDA in January 2026 for bladder cancer and lung cancer.
- ANKTIVA® received a conditional marketing authorization from the European Commission in February 2026.
- ANKTIVA® was authorized by the Pharmaceutical Administration Bureau of Macau in March 2026.
The players
ImmunityBio, Inc.
A biotechnology company focused on developing next-generation immunotherapies to activate the immune system and provide durable protection against cancer and infectious diseases.
Oberland Capital
An investment firm that provided the non-dilutive financing to ImmunityBio under the Revenue Interest Purchase Agreement (RIPA).
Nant Capital, LLC
An entity affiliated with ImmunityBio's Executive Chairman, Patrick Soon-Shiong, M.D., that converted $25 million of outstanding debt into equity.
Patrick Soon-Shiong, M.D.
The Founder, Executive Chairman, and Global Chief Medical and Scientific Officer of ImmunityBio.
Richard Adcock
The President and CEO of ImmunityBio.
What they’re saying
“This additional non-dilutive financing gives us the capacity to continue scaling our commercial efforts and expanding globally following recent ANKTIVA® approvals, while positioning us to take full advantage of the growth opportunities ahead.”
— Richard Adcock, President and CEO of ImmunityBio
“The non-dilutive financing from Oberland and the conversion of debt to equity by Nant Capital, reflect strong confidence in ImmunityBio's strategy and growth potential as a leading immunotherapy company paving the way for next-generation immunotherapy treatments.”
— Patrick Soon-Shiong, M.D., Founder, Executive Chairman and Global Chief Medical and Scientific Officer of ImmunityBio
What’s next
The company plans to use the additional financing to continue scaling its commercial efforts and expanding globally following the recent regulatory approvals for ANKTIVA®, while also advancing its broader immunotherapy pipeline.
The takeaway
The strengthening of ImmunityBio's balance sheet through non-dilutive financing and debt reduction demonstrates the company's commitment to driving the development and commercialization of its innovative immunotherapy treatments, positioning it for continued growth and success in the global market.
